COVID-19 (coronavirus)

Blood Program


Red and white blood cells (erythrocytes and leukocytes) are produced by hematopoietic stem cells (HSCs). HSCs have been used as stem cell therapies for more than 50 years in the form of bone marrow transplants. Cord blood is also a rich source of HSCs for therapeutic purposes. Advances in modern medicine, including new stem cell technologies and genetic engineering, are expanding the therapeutic use of HSCs.

The mission of the Blood Program at the Cedars-Sinai Regenerative Medicine Institute is to define the molecular mechanisms that regulate the production and maintenance of HSCs, the production of blood cells by HSCs (hematopoiesis) and the function of the different types of blood cells. We also seek to understand how dysregulation of these processes can cause disease such as bone marrow failure, immune deficiencies, infectious and inflammatory diseases, cancer and diseases associated with aging such as Alzheimer’s disease. Our hope is that understanding these mechanisms will reveal opportunities to manipulate the production and function of blood cells for novel treatments.


A macrophage engaging yeast particles. Macrophages adhere to the extracellular matrix, crawl around to explore their environment, and capture microbes and dead cells by phagocytosis. Consequently, their morphology is highly variable and constantly changing.


Helen Goodridge, PhD
Jlenia Guarnerio, MS, PhD
Akil Merchant, MD
Collaborative Research

Have Questions or Need Help?

Contact us if you have questions, or wish to learn more about the Board of Governors Regenerative Medicine Institute.

Board of Governors Regenerative Medicine Institute
Pavilion, Eighth Floor
8700 Beverly Blvd.
Los Angeles, CA 90048

Fax: 310-248-8066